Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

G1 Therapeutics Inc (GTHX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 688,666
  • Shares Outstanding, K 37,185
  • Annual Sales, $ 0 K
  • Annual Income, $ -85,290 K
  • 60-Month Beta 2.32
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.69
  • Number of Estimates 4
  • High Estimate -0.64
  • Low Estimate -0.74
  • Prior Year -0.70
  • Growth Rate Est. (year over year) +1.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.87 +33.53%
on 03/25/19
18.80 -1.49%
on 04/22/19
+4.12 (+28.61%)
since 03/22/19
3-Month
13.87 +33.53%
on 03/25/19
22.10 -16.22%
on 02/11/19
-1.06 (-5.41%)
since 01/22/19
52-Week
13.87 +33.53%
on 03/25/19
69.57 -73.38%
on 09/11/18
-20.41 (-52.43%)
since 04/20/18

Most Recent Stories

More News
New Research: Key Drivers of Growth for The Chemours, Superior Industries International, Caleres, G1 THERAPEUTICS, Vitamin Shoppe, and Ocular Therapeutix -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Chemours Company (NYSE:CC),...

CC : 39.34 (+0.13%)
GTHX : 18.52 (+3.99%)
VSI : 6.41 (-2.44%)
SUP : 5.96 (-3.09%)
CAL : 26.99 (-2.03%)
OCUL : 3.66 (+0.55%)
G1 Therapeutics to Present at the 18th Annual Needham Healthcare Conference

G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced Chief Executive Officer Mark Velleca, M.D., Ph.D., will present a company overview at the 18 Annual Needham Healthcare...

GTHX : 18.52 (+3.99%)
G1 Therapeutics to Present at Cowen and Company 39th Annual Healthcare Conference

G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced Chief Executive Officer Mark Velleca, M.D., Ph.D., will present a company overview at the Cowen and Company 39 Annual...

GTHX : 18.52 (+3.99%)
G1 Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results

-- Clinical program updates to be provided at Investor Day 2019 on March 6

GTHX : 18.52 (+3.99%)
G1 Therapeutics to Host Investor Day 2019 on March 6, 2019

G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host its Investor Day 2019 on Wednesday, March 6 in New York City, beginning at 8:00 a.m. ET and concluding...

GTHX : 18.52 (+3.99%)
G1 Therapeutics to Report Fourth Quarter and Full-Year 2018 Financial Results on February 28, 2019

G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to report financial results for the fourth quarter and full-year...

GTHX : 18.52 (+3.99%)
5 Domestic Stocks to Gain From Thaw in Trade Talks

The United States and China's outstanding disagreements on a few key issues could delay a favorable deal.

AAPL : 204.53 (+0.33%)
CTT : 9.41 (-4.27%)
GM : 39.50 (-1.99%)
F : 9.50 (-0.52%)
CCBG : 22.14 (-5.71%)
HABT : 10.16 (-0.97%)
GTHX : 18.52 (+3.99%)
REPH : 8.24 (-1.44%)
G1 THERAPEUTICS Enters Oversold Territory

G1 THERAPEUTICS (GTHX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

GTHX : 18.52 (+3.99%)
G1 Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference

G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D., will present a company overview at the 37 Annual J.P. Morgan...

JPM : 113.60 (+0.12%)
GTHX : 18.52 (+3.99%)
G1 Therapeutics Announces Positive Topline Results from Randomized Phase 2 Trial of Trilaciclib Showing Multi-Lineage Myelopreservation Benefits in 2nd-/3rd-Line Small Cell Lung Cancer

-- Clinically meaningful reductions in rates of granulocyte-colony stimulating factor (G-CSF) usage and red blood cell (RBC) transfusions

GTHX : 18.52 (+3.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade GTHX with:

Business Summary

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc....

See More

Key Turning Points

2nd Resistance Point 19.57
1st Resistance Point 19.05
Last Price 18.52
1st Support Level 17.75
2nd Support Level 16.97

See More

52-Week High 69.57
Fibonacci 61.8% 48.29
Fibonacci 50% 41.72
Fibonacci 38.2% 35.15
Last Price 18.52
52-Week Low 13.87

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar